Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin (2016 - 2026)

Gyre Therapeutics has reported EBT Margin over the past 15 years, most recently at 52.95% for Q4 2025.

  • Quarterly EBT Margin fell 5138.0% to 52.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.45% through Dec 2025, down 2527.0% year-over-year, with the annual reading at 4.45% for FY2025, 2527.0% down from the prior year.
  • EBT Margin was 52.95% for Q4 2025 at Gyre Therapeutics, down from 24.96% in the prior quarter.
  • Over five years, EBT Margin peaked at 45.93% in Q1 2024 and troughed at 1830.73% in Q1 2022.
  • The 5-year median for EBT Margin is 3.4% (2025), against an average of 404.26%.
  • Year-over-year, EBT Margin plummeted -150359bps in 2021 and then soared 185588bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 835.53% in 2021, then skyrocketed by 97bps to 22.46% in 2022, then tumbled by -1544bps to 369.38% in 2023, then skyrocketed by 100bps to 1.56% in 2024, then tumbled by -3292bps to 52.95% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBT Margin are 52.95% (Q4 2025), 24.96% (Q3 2025), and 8.36% (Q2 2025).